MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Search

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

67.01 2.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

64.72

Max

67.48

Belangrijke statistieken

By Trading Economics

Inkomsten

-317M

-142M

Verkoop

98M

452M

K/W

Sectorgemiddelde

24.641

66.418

Winstmarge

-31.342

Werknemers

423

EBITDA

-3.5M

281M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+36.02% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.9B

7.5B

Vorige openingsprijs

64.47

Vorige sluitingsprijs

67.01

Nieuwssentiment

By Acuity

21%

79%

62 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 apr 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Marktinformatie

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Marktinformatie

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Belangrijke Nieuwsgebeurtenissen

How Digital Currencies Have Helped Iran -- WSJ

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

36.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89 USD  36.02%

Hoogste 96 USD

Laagste 75 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

62 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat